title: A phase I/II trial of HIV SF2 gp120/MF59 vaccine in seronegative thais.AFRIMS-RIHES Vaccine Evaluation Group. Armed Forces Research Institute of Medical Sciences and the Research Institute for Health Sciences.
abstract: Fifty-two human immunodeficiency virus type 1, seronegative Thai adults from the community were enrolled in a double-blind, placebo controlled, phase I/II trial of HIV SF2 gp120/MF59 vaccine to determine the safety and immunogenicity of this recombinant, B clade, HIV envelope protein vaccine. Twenty-six subjects were enrolled at each of two sites in Thailand, Bangkok and Chiang Mai. Twelve subjects received placebo and 40 subjects received vaccine (50 microg). Subjects were immunized according to one of two schedules, 0, 1 and 4 or 0, 1 and 6 months. The frequency of adverse reactions was not different between placebo and vaccine subjects, nor between immunization schedules. Of vaccinees, all developed high-titer binding antibody to the immunogen (rgp120), 39 developed neutralizing antibody (NA) responses against homologous virus (HIV-1(SF2)), and 22 developed NA against heterologous virus (HIV-1(MN)). No subject demonstrated intercurrent HIV infection, however screening EIA reactivity occurred in 27% of recipients. Thus, this candidate HIV vaccine was found to be safe and immunogenic in Thai adults, laying the foundation for development of a subtype E construct in this population.
authors.affiliation: Armed Forces Research Institute of Medical Sciences (AFRIMS), Royal Thai Army Medical Department, 315/6 Rajvithi Road, Bangkok, Thailand.
authors.forename: S
authors.initials: S
authors.lastname: Nitayaphan
authors.forename: C
authors.initials: C
authors.lastname: Khamboonruang
authors.forename: N
authors.initials: N
authors.lastname: Sirisophana
authors.forename: P
authors.initials: P
authors.lastname: Morgan
authors.forename: J
authors.initials: J
authors.lastname: Chiu
authors.forename: A M
authors.initials: AM
authors.lastname: Duliege
authors.forename: C
authors.initials: C
authors.lastname: Chuenchitra
authors.forename: T
authors.initials: T
authors.lastname: Supapongse
authors.forename: K
authors.initials: K
authors.lastname: Rungruengthanakit
authors.forename: M
authors.initials: M
authors.lastname: deSouza
authors.forename: J R
authors.initials: JR
authors.lastname: Mascola
authors.forename: K
authors.initials: K
authors.lastname: Boggio
authors.forename: S
authors.initials: S
authors.lastname: Ratto-Kim
authors.forename: L E
authors.initials: LE
authors.lastname: Markowitz
authors.forename: D
authors.initials: D
authors.lastname: Birx
authors.forename: V
authors.initials: V
authors.lastname: Suriyanon
authors.forename: J G
authors.initials: JG
authors.lastname: McNeil
authors.forename: A E
authors.initials: AE
authors.lastname: Brown
authors.forename: R A
authors.initials: RA
authors.lastname: Michael
mesh_terms: D016915:AIDS Vaccines / Q000276:immunology*; D000328:Adult; D004311:Double-Blind Method; D005260:Female; D005500:Follow-Up Studies; D015483:HIV Antibodies / Q000097:blood; D015699:HIV Envelope Protein gp120 / Q000276:immunology*; D018023:HIV Seronegativity; D006801:Humans; D008213:Lymphocyte Activation; D008297:Male; D008875:Middle Aged; D013785:Thailand; D014614:Vaccines, Synthetic / Q000276:immunology*
chemical_list: D016915:AIDS Vaccines; D015483:HIV Antibodies; D015699:HIV Envelope Protein gp120; D014614:Vaccines, Synthetic